• The market size of the proton pump inhibitor (PPI) market,
• The leading players and products of the PPI market, including sales volume and product pros and cons,
• and alternatives to PPI and their popularity

Market Size and Leading Players and Products

• The global GERD therapeutics market (which includes antacids, H2 Receptor Blockers, PPIs, and pro-kinetic agents) is anticipated to shrink by 2.9 percent each year through 2025. In 2016, the global GERD therapeutics market was $5.66 billion (with an anticipated value of $4.34 billion in 2025.
• PPIs are growing, however: For the PPI market specifically, the anticipated growth rate is 5 percent annually.
•  Leading players in the U.S. PPI market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eisai Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson and Johnson, Pfizer Inc., Proctor and Gamble, and Takeda Pharmaceuticals.
• As of 2017, Nexium is the biggest-selling PPI with global sales of $72.5 billion from 1992-2017.

Nexium

• Nexium is owned by AstraZeneca.
• Pro: When it was introduced, some studies indicated that Nexium demonstrates higher healing rates compared to omeprazole.
• Pro: Nexium is low-cost.
• Con: Side effects include nausea, headaches, dry mouth, diarrhea, allergic reactions, and the development of kidney stones.

Alternatives to PPIs

•  Alternatives to PPIs include omeprazole (such as Prilosec), pantoprazole (such as Protonix), and lansoprazole (such as Prevacid).

Summary of Early Findings in Relation to Goals